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tence compared to those who started on a generic and switched to a brand.
CONCLUSIONS: Initiating or switching to generic therapy is associated with signif-
icantly higher compliance and greater therapy persistence compared to initiating
or switching to brand medications.
PIH30
ASSESSING INCONSISTENCIES IN ADHERENCE RESEARCH: A SYSTEMATIC
REVIEW
Mccann E1, Al-Dakkak I1, McAlister A2, Patel S1
1HERON Health, Luton, UK, 2HERON Health, Somerville, NJ, USA
OBJECTIVES: Non-adherence to prescription medication is a serious problem. Ac-
curate assessment of adherence is important for improving patients’ health out-
comes and informing decisions made by providers and payers. This study exam-
ined how adherence was defined, measured, and reported in the scientific
literature. METHODS: A systematic review of studies reporting on adherence to
prescription medication for chronic diseases was conducted. Embase® and MED-
LINE® databases were searched. In addition, bibliographies of identified review
papers were assessed for inclusion. Mean overall adherence was estimated using a
random effects model. RESULTS: The review included 266 studies that met pre-
defined inclusion criteria. The definition of non-adherence varied across studies;
73.6% of all studies defined non-adherence as missed/skipped doses only, while
24.3% defined it as discontinuation of therapy only, and 2.1% defined it as either.
Adherencewas recordedusing different tools including claimsdata (55.2%), patient
self-reports (30.5%), pill counts (12.8%), and laboratory tests (1.5%). Furthermore,
included studies used various metrics to assess determinants of adherence, and
some studies used more than one measure. The most commonmetrics were odds
ratios (65.6%), regression coefficients (13.0%), hazard ratios (11.2%), and relative
risks (5.4%). Themeta-analysis showed that themean overall adherence was high-
est in studies that defined non-adherence as missed/skipped doses only (51.7% of
all participants). Mean adherence in studies defining non-adherence as discontin-
uation of therapy only and in studies defining it as missed/skipped doses or dis-
continuation of therapy was 45.4% and 45.0%, respectively. CONCLUSIONS: Incon-
sistencies in the adherence literature pose a challenge to the interpretation,
usefulness, and synthesis of adherence data. There is a clear need formethodolog-
ical standardisation in adherence research and assessment.
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OBJECTIVES: To assess the impact of reducing the frequency of oral therapies from
multiple-dosing schedules to a once-daily (od) dosing schedule on adherence, com-
pliance, and the associated economic impact.METHODS: All relevant studies were
searched using electronic databases (MEDLINE® and Embase®). The studies as-
sessing adherence with od, twice-daily (bid), thrice-daily (tid), and four-times daily
(qid) dosing schedules, and costs associated with optimal/suboptimal adherence
among patients with acute and chronic diseases, were included. There was no
restriction on the treatments assessed other than that they were delivered orally.
Comparisons of effect estimates across studies were pooled and analyzed using a
DerSimonian and Laird random-effects model. RESULTS: Forty-three studies met
the inclusion criteria of the review, ofwhich 33 studies compared once-daily dosing
schedulewithmultiple-dosing schedules. Data on adherence and compliancewere
available for studies in depression, HIV, hypertension, and respiratory tract infec-
tions (RTIs). Among these conditions, the overall results indicated that od schedule
was associated with higher adherence rates [Odds Ratio (OR): 2.34; 95% Confidence
Interval (CI): 1.31, 4.17; p0.004 for od versus bid/tid dosing] and compliance rates
(OR: 5.76; 95% CI: 1.89, 17.57; p0.001 for od versus bid dosing) compared with
multiple-dosing schedules. From a health economic perspective, it was observed
that higher adherence rates with od schedule (relative to multiple-dosing sched-
ules) prescribed in cardiovascular disorders, renal transplant, pain, RTIs, and ul-
cerative colitis were associated with lower costs of healthcare resource utilization.
For example, treatment costs in renal transplant patients demonstrated total, per-
patient cost savings of $9411 over a 5-year time horizonwith od regimen compared
with bid regimen. CONCLUSIONS: The present evidence base suggests that reduc-
ing the dose frequency from multiple dosing to once-daily dosing schedule could
improve adherence and compliance among patients with acute and chronic dis-
eases. Improving adherence was associated with further decreases in health care
costs.
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OBJECTIVES: Non-adherence to treatment predicts poorer health status. Patient
characteristics underlying intentional (INA) and unintentional (UNA) non-adher-
encewere analyzed among eleven costly chronic conditions.METHODS:Data from
U.S. 2011 National Health and Wellness Survey included 30,981 (of 75,000) respon-
dents reporting prescriptions for: asthma, pain, congestive heart failure, COPD,
diabetes, hypertension, depression, bipolar disorder, peripheral vascular disease,
transient ischemic attack, and stroke. Morisky Medication Adherence Scale items
were summed to create INA (“stop taking medicine when feeling better” and
“. . .when feeling worse”) and UNA (“forget to take medicine” and “careless about
taking medicine”) scores ranging from 0adherence to 2high non-adherence.
Across conditions, two logistic regressions predicted INA and UNA (1 vs. 0) from
gender, age, marital status, college education, income, race/ethnicity, exercise12
timesmonthly, alcohol consumption2 timesweekly, cigarette smoking, employ-
ment, health insurance, BMI category, and adjusted Charlson Comorbidity Index
(CCI) score. RESULTS: Adjusting for covariates, significant predictors of INA and
UNA (odds ratios in parentheses for INA and UNA, respectively), were: female
gender (1.32/1.09), younger age (1.04/1.02), education (non-significant [n.s.]/1.13),
employment (n.s./1.13), uninsured status (1.24/n.s.), income $50k (vs. $50k-
$75k: 1.15/n.s.; vs. $75k: 1.20/1.11), Hispanic (1.60/1.20), African American (1.47/
1.21), or other (1.52/1.28) race/ethnicity (vs.White), non-exercise (1.19/1.39), alcohol
consumption (1.12/1.16), smoking (1.25/n.s.), overweight (0.90/1.16), obesity (0.81/
1.37), and high CCI (1.03/1.03); all p.05. CONCLUSIONS: Women, non-Whites,
younger, and poorer respondents, non-exercisers, alcohol consumers, and more
comorbid respondents were at greater risk of non-adherence. Obesity/overweight
predictedhigherUNAbut lower INA risk, perhaps fromobstacles to adherence (e.g.,
complex treatment regimens) but more adherent intentions due to obesity-related
mortality risk. Employment and education were associated only with UNA (per-
haps due to difficulty tracking treatment regimens while engaged in complex oc-
cupations). Smoking and uninsured status were associated only with INA. Simpli-
fied treatments may improve UNA while better access may reduce non-adherence
overall.
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OBJECTIVES: Compliance or adherence to regimens and persistence over time are
common concerns among doctors. The impact of oral once-daily [QD] or twice-
daily [BID dosing regimen on adherence and persistence is unclear, and may po-
tentially affect clinical and economic outcomes. This review aims to identify stud-
ies that identified the impact of QD vs. BID dose regimens of oral treatments on
adherence and persistence in several disease areas that require chronic medica-
tion use.METHODS: Relevant articles were identified through a systematic litera-
ture review from PubMed (2000-2011) using the terms adherence, oral, administra-
tion and dosage, QD, BID, once daily, twice daily, and treatment. Another search
explored the secondary and tertiary references of relevant studies identified
through the bibliographies of articles found in the primary search. RESULTS: Re-
search articles (N16) that met the search criteria comprised the following disease
areas: HIV/AIDS (10 articles), diabetes, ulcerative colitis (2), depression, hyperten-
sion and chronic heart failure. 63% (10/16) of the studies observed improvement on
adherence with the oral QD treatment in comparison to the BID regimen. Of those,
6 were for HIV drugs, 1 for hypertension, 1 for ulcerative colitis, 1 for diabetes and
1 for depression. Articles evaluating drugs for the treatment of ulcerative colitis,
HIV (4) and chronic heart failure found no impact on adherence. Persistence was
measured in 25% (4/16) of the studies, identified the following therapeutic areas:
depression, diabetes and HIV. 50% (2/4) found significantly greater persistence
among patients in the QD regimen versus BID regimens. Studies on HIV medica-
tions did not find any impact on persistence. CONCLUSIONS: Themajority of stud-
ies evaluating adherence of oral QD versus BID treatments for long-term drug
treatments observed improvement of adherence with QD versus BID treatment.
The impact of oral drug dosing frequency on persistence remains unclear and can
vary by therapeutic areas.
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OBJECTIVES: It is important to study the extent to which Medicare Part D’s unique
benefit structure (with a gap in the middle) affects seniors’ adherence to prescrip-
tion medications. Therefore, this study had following objectives: 1) To identify
characteristics of beneficiaries reaching and not reaching the coverage gap, and 2)
To study the impact of a complete gap in coverage on beneficiaries’ adherence to
prescriptionmedications.METHODS: This was a retrospective quasi-experimental
analysis with matched control group using a nationally representative sample of
Part D enrollees of stand-alone prescription drug plans (PDPs) from2008Centers for
Medicare andMedicaid (CMS) Part D and summary datasets. In addition to studying
differences in characteristics of those who did and did not reach the coverage gap
in 2008, adherence to oral medications taken from one or more of the seven pre-
defined therapeutic classes was measured using Medication Possession Ratio
(MPR). Appropriate statistical tests for significance were performed using SAS 9.1.
RESULTS: A quarter of our sample (24.42%) reached the coverage gap in 2008,
mostly by end of September. Of these, 12.10% (2.97% of the total sample) reached
the catastrophic coverage phase. Although the two groups had similar demo-
graphic attributes, beneficiaries reaching the coverage gap had higher prescription
medication use compared to those not reaching the coverage gap (11.25(4.63) vs.
7.39(3.75)). Beneficiaries reaching the gap experienced significantly greater reduc-
tions in adherence (3.00% more for beta-blockers to 9.00% more for oral anti-dia-
betic agents, p-value0.0001), compared to those not reaching the gap. During the
A197V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
